CYH33 + letrozole + palbociclib

CYH33 + letrozole + palbociclib is a combination regimen for cancer therapy under investigation, specifically targeting advanced or metastatic breast cancer. - **CYH33** is an investigational selective inhibitor of phosphatidylinositol 3-kinase alpha (PI3Kα), which inhibits tumor cell growth by blocking downstream PI3K-Akt signaling, a pathway commonly activated in multiple cancers due to PIK3CA mutations. - **Letrozole** is a nonsteroidal aromatase inhibitor that suppresses estrogen synthesis, thereby blocking estrogen-driven growth in hormone receptor–positive breast cancer. - **Palbociclib** is an oral, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, which prevents cell cycle progression through G1 phase arrest, further inhibiting tumor proliferation in HR-positive breast cancer. This triple combination proposes simultaneous blockade of PI3Kα (CYH33), CDK4/6 (palbociclib), and estrogen synthesis (letrozole), a rational multi-targeted approach for advanced breast cancer, particularly in cases harboring PIK3CA mutations and HR positivity.

Other names

CYH33 + letrozole + palbociclib